Rapamycin affects tissue plasminogen activator and plasminogen activator inhibitor 1 expression: A potential prothrombotic mechanism of drug-eluting stents

Angiology

Volumn 63, Issue 5, 2012, Pages 330-335

  Ma, Qian ^a   Zhou, Yujie ^a   Nie, Xiaomin ^a   Yu, Miao ^a   Gao, Fei ^a   Wang, Zhijian ^a   Ge, Hailong ^a   Jia, Dean ^a   Yang, Shiwei ^a   Liu, Xiaoli ^a   Han, Hongya ^a   Hu, Bin ^a   Shen, Hua ^a   Xu, Xiaohan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

drug eluting stent; endothelial cell; plasminogen activator inhibitor 1; rapamycin; thrombosis; tissue plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; RAPAMYCIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; RESTENOSIS; THROMBOSIS; UMBILICAL VEIN ENDOTHELIAL CELL;

CARDIOVASCULAR AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG-ELUTING STENTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTHESIS DESIGN; RNA, MESSENGER; SIROLIMUS; THROMBOSIS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; UP-REGULATION;

EID: 84861841172     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711418219     Document Type: Article

References (34)

1. van Werkum JW, Heestermans AA, de Korte FI, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation. 2009 ; 119 (6). 828-834
2. Chen JP, Crisco LV, Jabara R, King SB. Late angiographic stent thrombosis: the LAST straw for drug-eluting stents?. Angiology. 2008 ; 59 (6). 667-675
3. Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007 ; 115 (8). 1051-1058
4. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009 ; 119 (25). 3198-3206
5. Sehgal SN.. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998 ; 31 (5). 335-340
6. Feenstra J, Vermeer RJ, Stricker BH.. Mesenteric venous thrombosis attributed to docetaxel. Am J Clin Oncol. 2000 ; 23 (4). 353-354
7. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation. 2004 ; 78 (2). 264-268
8. Steffel J, Latini RA, Akhmedov A, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005 ; 112 (13). 2002-2011
9. Camici GG, Steffel J, Amanovic I, et al. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur Heart J. 2010 ; 31 (2). 236-242
10. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000 ; 102 (6). 624-629
11. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 ; 346 (23). 1773-1780
12. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 ; 349 (14). 1315-1323
13. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ.. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet. 2004 ; 364 (9434). 583-591
14. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004 ; 364 (9444). 1519-1521
15. Camenzind E, Steg PG, Wijns W. 2006:
16. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005 ; 45 (6). 954-959
17. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL.. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol. 2005 ; 45 (6). 941-946
18. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL.. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol. 2005 ; 95 (12). 1469-1472
19. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 ; 356 (10). 998 - l008
20. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005 ; 293 (17). 2126-2130
21. Schwartz RS, Chronos NA, Virmani R.. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004 ; 44 (7). 1373-1385
22. Pendyala LK, Yin X, Li J, Chen JP, Chronos N, Hou D.. The first-generation drug-eluting stents and coronary endothelial dysfunction. JACC Cardiovasc Interv. 2009 ; 2 (12). 1169-1177
23. Kim JW, Suh SY, Choi CU, et al. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent. JACC Cardiovasc Interv. 2008 ; 1 (1). 65-67
24. Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002 ; 13 (3). 183-188
25. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001 ; 104 (10). 1188-1193
26. US Food and Drug Administration, Center for Devices and Radiological Health. CYPHERTM sirolimus-eluting coronary stent on RAPTORTM over-the-wire delivery system; CYPHERTM sirolimus-eluting coronary stent on RAPTORRAIL" rapid exchange delivery system. http://www.fda.gov/cdrh/pdf2/p020026.html. Accessed December 17, 2004
27. Kereiakes DJ, Choo JK, Young JJ, Broderick TM.. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004 ; 5 (1). 9-15
28. Koide H, Asai T, Furuya K, et al. Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector. Biol Pharm Bull. 2011 ; 34 (5). 602-608
29. Steffel J, Luscher TF, Tanner FC.. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006 ; 113 (5). 722-731
30. Guha M, Mackman N.. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002 ; 277 (35). 32124-32132
31. Eto M, Kozai T, Cosentino F, Joch H, Lüscher TF.. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002 ; 105 (15). 1756-1759
32. Viswambharan H, Ming XF, Zhu S, et al. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res. 2004 ; 94 (7). 918-925
33. Blum S, Issbruker K, Willuweit A, et al. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem. 2001 ; 276 (36). 33428-33434
34. Jin HK, Ahn SH, Yoon JW, et al. Rapamycin down-regulates inducible nitric oxide synthase by inducing proteasomal degradation. Biol Pharm Bull. 2009 ; 32 (6). 988-992